





Formula 2

and pharmaceutically acceptable salts, prodrugs, tautomers, and solvates, thereof.

3. A pharmaceutical composition comprising a compound as defined in claims 1 or 2 and a pharmaceutically acceptable carrier, vehicle or diluent.

4. A method of treating any mammal, preferably a human, affected by cancer or psoriasis which comprises administering to the affected individual a therapeutically effective amount of a compound as defined in claims 1 or 2.

5. A method according to claim 4 wherein the mammal is a human and he is affected by cancer.

6. A method according to claim 5 wherein the patient has a refractory cancer that does not respond favourably to other treatments.

7. The method of claim 5 wherein the cancer is selected from prostate cancer, breast cancer, hepatocellular carcinoma, melanoma, colorectal cancer, renal cancer, ovarian cancer, NSCL cancer, epithelial cancer, pancreatic cancer and tumors that overexpress the Her2/neu oncogene.

8. The use of a compound as defined in claim 1 or 2 in the manufacture of a medicament.

9. The use of a compound as defined in claim 1 or 2 in the manufacture of a medicament for the treatment of cancer, psoriasis, viral infection or fungal infection.

10. A kit comprising separate containers containing a pharmaceutical composition comprising a compound as defined in claims 1 or 2 and a reconstituting agent.

11. A process for the preparation of a compound as defined in claims 1 or 2.

12. A process according to claim 11 characterized in that it uses 4-methylhexanoic acid as starting material.

13. A process according to claim 11 characterized in that it uses (4S)-methylhexanoic acid.